Trial Profile

A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tanruprubart (Primary)
Indications Huntington's disease
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
Sponsors Annexon

27 Apr 2023 Final results presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
03 Nov 2022 According to an Annexon media release, data from this study will be presented at Huntingtons Study Group (HSG) 2022 Annual Meeting
18 Sep 2022 Results assessing the safety, pharmacokinetics/pharmacodynamics, biomarkers, and efficacy of ANX005 in patients with huntingtons disease, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com